Stockscreener 앱 받기
0.00
100.00%
-3.20
전일 마감가:
$3.20
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$75.50M
수익:
$709.00K
순이익/손실:
$-43.14M
주가수익비율:
0.00
EPS:
-4.54
순현금흐름:
$-20.35M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$4.75
OncoCyte Corporation Stock (OCX) Company Profile
명칭
OncoCyte Corporation
전화
510-775-0515
주소
1010 Atlantic Avenue, Suite 102, Alameda, CA
OCX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCX
OncoCyte Corporation
|
0.00 | 75.50M | 709.00K | -43.14M | -20.35M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
OncoCyte Corporation Stock (OCX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-28 | 개시 | Lake Street | Buy |
| 2022-05-24 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-03-17 | 재개 | Needham | Buy |
| 2021-01-07 | 업그레이드 | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | 개시 | BTIG Research | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | 재확인 | The Benchmark Company | Speculative Buy |
| 2020-07-01 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | 개시 | Needham | Buy |
| 2019-02-13 | 개시 | Piper Jaffray | Overweight |
| 2019-01-29 | 업그레이드 | Janney | Neutral → Buy |
| 2018-12-19 | 재개 | Lake Street | Buy |
모두보기
OncoCyte Corporation 주식(OCX)의 최신 뉴스
Insight Molecular Diagnostics moves to Nashville - Nashville Post
Oncocyte Exits Irvine, Rebrands as Insight Molecular Diagnostics - Orange County Business Journal
Oncocyte Changes Name to Insight Molecular Diagnostics, Relocates HQ to Nashville - MarketScreener
OncoCyte Rebrands to Insight Molecular Diagnostics - TipRanks
OncoCyte changes name to Insight Molecular Diagnostics - TipRanks
Insight Molecular Diagnostics (IMDX) Rebrands and Relocates Headquarters | OCX Stock News - GuruFocus
Oncocyte Changes Name To Insight Molecular Diagnostics - marketscreener.com
Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville - The Manila Times
Midday Stock Roundup: GEN Restaurants Down. BJ’s Restaurants Up - Orange County Business Journal
Lake Street Capital Forecasts Strong Price Appreciation for OncoCyte (NASDAQ:OCX) Stock - Defense World
Lake Street Raises Price Target for OncoCyte (OCX) to $8.00 | OC - GuruFocus
Lake Street Raises Price Target for OncoCyte (OCX) to $8.00 | OCX Stock News - GuruFocus
Oncocyte (OCX) Gains Favorable Reimbursement for GraftAssureCore Test | OCX Stock News - GuruFocus
OncoCyte (OCX) Price Target Raised Amid Reimbursement Boost | OC - GuruFocus
OncoCyte reports Medicare boosts reimbursement for GraftAssureCore - TipRanks
OncoCyte (OCX) Price Target Raised Amid Reimbursement Boost | OCX Stock News - GuruFocus
OncoCyte price target raised to $8 from $5 at Lake Street - TipRanks
Oncocyte Corp Says New CMS Reimbursement Price Rate Of $2,753 Per Result For Graftassurecore Assay - marketscreener.com
Medicare Boosts Reimbursement for Oncocyte's Flagship Technology - The Manila Times
Medicare Approves 24% Higher Payment for Oncocyte's Transplant Test: $1B Market Opportunity Expands - Stock Titan
OncoCyte targets 20 transplant center milestone and upcoming FDA submission while advancing rebranding initiative - MSN
OncoCyte Corp’s Earnings Call: Optimism Amid Challenges - TipRanks
OncoCyte (NASDAQ:OCX) Earns “Buy” Rating from Needham & Company LLC - Defense World
OncoCyte (OCX) Seeks FDA Approval by 2026 - GuruFocus
OncoCyte Corporation (NASDAQ:OCX) Q1 2025 Earnings Call Transcript - Insider Monkey
Needham maintains Buy on OncoCyte, price target at $4.25 - Investing.com Australia
Needham maintains Buy on OncoCyte, price target at $4.25 By Investing.com - Investing.com Nigeria
OncoCyte Corp (OCX) Q1 2025 Earnings Call Highlights: Strategic Advances in Transplant Testing ... - Yahoo Finance
OncoCyte Corp (OCX) Q1 2025 Earnings Call Highlights: Strategic - GuruFocus
OncoCyte (OCX) Maintains 'Buy' Rating and Price Target by Needha - GuruFocus
Earnings call transcript: OncoCyte’s Q1 2025 revenue beats expectations By Investing.com - Investing.com Nigeria
OncoCyte Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: OncoCyte’s Q1 2025 revenue beats expectations - Investing.com
OncoCyte: Q1 Earnings Snapshot - San Antonio Express-News
OncoCyte Corp (OCX) Q1 2025 Earnings: Revenue Soars to $2.1 Mill - GuruFocus
Oncocyte Reports Q1 2025 Results and Business Progress - The Manila Times
Oncocyte Corp. Reports Q1 2025 Revenue of $2.1 Million and Plans Company Renaming - Nasdaq
Oncocyte Corp SEC 10-Q Report - TradingView
Oncocyte to Release First Quarter 2025 Results on May 12, 2025 - The Manila Times
Oncocyte To Release First Quarter 2025 Results On May 12, 2025 - Barchart.com
Best Momentum Stocks to Buy for May 6th - The Globe and Mail
Geode Capital Management LLC Has $326,000 Stock Position in OncoCyte Co. (NASDAQ:OCX) - Defense World
Oncocyte Provides Positive Update on Clinical Trial Progress | O - GuruFocus
Why Tesla Stock Hit the Brakes Today - The Globe and Mail
AP PHOTOS: US stocks sink after a weak report on the economy - The Globe and Mail
Oncocyte (OCX) Advances Towards Crucial Clinical Trial for Trans - GuruFocus
Oncocyte advances toward clinical trial for transplant test By Investing.com - Investing.com India
Oncocyte advances toward clinical trial for transplant test - Investing.com Australia
Oncocyte Provides Positive Update on Clinical Trial Progress - The Manila Times
OncoCyte Corporation (OCX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
OncoCyte Corporation 주식 (OCX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SMITH PATRICK W | 10% Owner |
Feb 07 '25 |
Buy |
2.05 |
1,077,600 |
2,209,080 |
2,872,671 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Feb 06 '25 |
Buy |
2.05 |
5,165,695 |
10,589,675 |
11,410,100 |
| SMITH PATRICK W | 10% Owner |
Jan 31 '25 |
Buy |
2.01 |
890 |
1,789 |
1,795,046 |
| SMITH PATRICK W | 10% Owner |
Feb 04 '25 |
Buy |
2.02 |
25 |
50 |
1,795,071 |
| SMITH PATRICK W | 10% Owner |
Jan 29 '25 |
Buy |
2.01 |
3,880 |
7,799 |
1,793,838 |
| SMITH PATRICK W | 10% Owner |
Jan 30 '25 |
Buy |
2.01 |
318 |
639 |
1,794,156 |
| SMITH PATRICK W | 10% Owner |
Jan 14 '25 |
Buy |
2.15 |
10,386 |
22,323 |
1,789,958 |
| SMITH PATRICK W | 10% Owner |
Jan 13 '25 |
Buy |
2.08 |
5,669 |
11,792 |
1,779,572 |
| SMITH PATRICK W | 10% Owner |
Dec 26 '24 |
Buy |
2.13 |
90,219 |
192,166 |
1,773,903 |
| Arno Andrew | Director |
Dec 26 '24 |
Buy |
2.11 |
12,500 |
26,350 |
81,554 |
0.68%
0.50%
자본화:
|
볼륨(24시간):